Vicore Pharma

Sweden
Mölndal, Västra Götaland, Sweden, 413 83

Company profile

Vicore Pharma company profile

Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.

Business identity

Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2009-01-01, Year

Headquarters

Postal code
413 83
Country code
SE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
4
Total equity funding
$104.2M
Last funding
Post IPO Equity / $48M / 2025-11-13
Last equity funding
Post IPO Equity / $48M
Investors
12
Lead investors
1
Articles
104
Exited on
2015-12-11

Founders and investors

Lead investors

Sanofi

Investors

HealthCapInvusLifeArcOrbiMedSanofi